GOSS
$0.42-0.03 (-6.55%)
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
Recent News
Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory Environment
Gossamer Bio, Inc. (NASDAQ:GOSS) is included in our list of the 10 most active penny stocks to buy. As of March 16, 2026, Gossamer Bio, Inc. (NASDAQ:GOSS) has support from 44% of analysts who maintain a “Buy” rating for the stock. The consensus price target of $1.00 indicates an upside potential of 117.39%. Amid an […]
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -7.14% and +81.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Gossamer Bio: Q4 Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 21 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 20 cents per share.
Gossamer Bio options imply 46.1% move in share price post-earnings
Pre-earnings options volume in Gossamer Bio (GOSS) is normal with puts leading calls 19:3. Implied volatility suggests the market is anticipating a move near 46.1%, or 0c, after results are released. Median move over the past eight quarters is 3.5%.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the u
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.